Language:
Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
labmedica.com
Clinical Chemistry
Features Subscription Partner Sites Journal Info
SANYO EUROPE LTDFOCUS DIAGNOSTICS, INC.THE BINDING SITE

Fecal Test Aids Colonoscopy Screening

By Labmedica International staff writers
Posted on 29 Nov 2011


Fecal immunochemical testing (FIT) is more effective in its health benefits at all levels of colonoscopy capacity.

When compared to guaiac fecal occult blood testing (gFOBT), FIT assays have similar or even lower costs and may reduce mortality from colorectal cancer.

Scientists at the Erasmus Medical Center (Rotterdam, the Netherlands) used the MISCAN-Colon microsimulation model, which simulates the relevant biographies of a large population from birth to death both without screening, as well as with changes that would occur in screening programs. They estimated the number of colonoscopies, costs, and health effects of different screening strategies using gFOBT and FIT, various age ranges and multiple surveillance strategies.

The model predicts that FIT is both cost-effective and clinically beneficial for detecting colon rectal cancer (CRC). They found that for a screening scenario for people ages 45 to 80 years in which there is unlimited colonoscopy capacity, screening intensively with the lowest FIT cutoff level for referral to colonoscopy of 50 ng hemoglobin/mL, provided optimal health benefits for cost. For a scenario with limited colonoscopy capacity, FIT with a higher cutoff level performed better than gFOBT and was more effective if the colonoscopy capacity was expanded.

In many countries, wait times for colonoscopy screenings can take up to 12 weeks. Screening with gFOBT has been proven to reduce mortality from CRC. However, the effectiveness of the screening depends partly on attendance at all screening rounds and on diagnostic yield, which is the proportion of individuals found with adenomas or CRC. FIT may increase attendance and diagnostic yield compared to gFOBT, and may cause fewer false positive tests. Because of these advantages, FIT is of increasing interest in the field.

The authors concluded, "It should be noted that FOBT screening can become considerably more effective if colonoscopy capacity is expanded. Efforts should therefore be undertaken to achieve an increased colonoscopy capacity.” The study was published on November 9, 2011, in the Journal of the National Cancer Institute.

Related Links:

Erasmus Medical Center






Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?

ADVERTISEMENT
GLOBETECH PUBLISHING



ELISA Reader
ELISA Reader
Rapid Pathogen Tests
Rapid Pathogen Tests
Face Shield
Face Shield

More Products

CELLAVISION AB
AACC

Latest Clinical Chemistry News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
ELGA LABWATER:
ELGA ensures largest latam lab is working night and day

Download Whitepaper
VISION-SCIENCES, INC.
Events
Journals of Clinical Laboratory update
23 Jun 2012 - 24 Jun 2012


FIME 2012 – Florida International Medical Exhibition.
08 Aug 2012 - 10 Aug 2012


ECI - European Congress of Immunology
05 Sep 2012 - 08 Sep 2012


More events
Latest Issue

View Digital Edition
Subscribe / Renew
GREINER-BIO-ONE'
EUROIMMUN AG
GLOBETECH PUBLISHING
BRAND GMBH + CO
BioPorto Diagnostics
PURITAN MEDICAL
INOVA DIAGNOSTICS INC
  labmedica.com Copyright © 2000-2012 Globetech Media. All rights reserved.
Privacy Policy